CY1115325T1 - Λιποσωματα για διανομη φαρμακων και μεθοδοι παρασκευης αυτων - Google Patents

Λιποσωματα για διανομη φαρμακων και μεθοδοι παρασκευης αυτων

Info

Publication number
CY1115325T1
CY1115325T1 CY20121100997T CY121100997T CY1115325T1 CY 1115325 T1 CY1115325 T1 CY 1115325T1 CY 20121100997 T CY20121100997 T CY 20121100997T CY 121100997 T CY121100997 T CY 121100997T CY 1115325 T1 CY1115325 T1 CY 1115325T1
Authority
CY
Cyprus
Prior art keywords
liposomes
preparation
methods
another aspect
dispensing medicines
Prior art date
Application number
CY20121100997T
Other languages
English (en)
Inventor
Anders Falk Vikbjerg
Sune Allan Petersen
Fredrik Melander
Jonas Rosager Henriksen
Kent Jørgensen
Original Assignee
Liplasome Pharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liplasome Pharma Aps filed Critical Liplasome Pharma Aps
Publication of CY1115325T1 publication Critical patent/CY1115325T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει λιποσώματα που είναι χρήσιμα για τη διανομή βιοδραστικών παραγόντων όπως θεραπευτικών μέσων. Μεταξύ άλλων, τα λιποσώματα της εφευρέσεως είναι ικανά να διανείμουν το ωφέλιμο φορτίο τους σε θέσεις αυξημένης ενεργότητας εκκριτικής φωσφολιπάσης Α2 (sPLA2), λόγω του ότι η φωσφολιπάση Α2 (PLA2) θα υδρολύσει λιπίδια του λιποσώματος. Κατά συνέπεια, τα λιποσώματα της εφευρέσεως μπορούν, π.χ. να χρησιμοποιηθούν σε σχέση με τη θεραπεία του καρκίνου. Μία άλλη όψη της εφευρέσεως είναι μία λιποσωμική σύσταση που περιλαμβάνει το λιπόσωμα της εφευρέσεως. Ακόμη μία άλλη όψη είναι μία μέθοδος παραγωγής μίας λιποσωμικής συστάσεως της εφευρέσεως.
CY20121100997T 2008-05-23 2012-10-23 Λιποσωματα για διανομη φαρμακων και μεθοδοι παρασκευης αυτων CY1115325T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200800717 2008-05-23
EP08014793A EP2123258A1 (en) 2008-05-23 2008-08-20 Liposomes for drug delivery
EP09749940A EP2299977B1 (en) 2008-05-23 2009-05-25 Liposomes for drug delivery and methods for preparation thereof

Publications (1)

Publication Number Publication Date
CY1115325T1 true CY1115325T1 (el) 2017-01-04

Family

ID=40221427

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100997T CY1115325T1 (el) 2008-05-23 2012-10-23 Λιποσωματα για διανομη φαρμακων και μεθοδοι παρασκευης αυτων

Country Status (14)

Country Link
US (2) US20120009243A1 (el)
EP (2) EP2123258A1 (el)
JP (1) JP5767580B2 (el)
CN (1) CN102065840B (el)
AU (1) AU2009248673B2 (el)
CA (1) CA2725529C (el)
CY (1) CY1115325T1 (el)
DK (1) DK2299977T3 (el)
ES (1) ES2393170T3 (el)
HR (1) HRP20120776T1 (el)
PL (1) PL2299977T3 (el)
PT (1) PT2299977E (el)
SI (1) SI2299977T1 (el)
WO (1) WO2009141450A2 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
DK177532B1 (en) * 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) * 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
WO2011098578A2 (en) 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
CA2848173C (en) * 2011-05-10 2019-07-02 The Penn State Research Foundation Ceramide anionic liposome compositions
CN102579350B (zh) * 2012-03-02 2013-04-24 海南灵康制药有限公司 右旋布洛芬脂质体固体制剂
US10383822B2 (en) 2012-08-10 2019-08-20 Taiho Pharmaceutical Co., Ltd. Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
MA37931A1 (fr) * 2012-08-13 2016-07-29 Teni Boulikas Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite
CN103169659A (zh) * 2012-11-23 2013-06-26 杭州师范大学 一种奥沙利铂长循环脂质体及其应用
BR112015022416A2 (pt) * 2013-03-13 2017-10-24 Bioasis Technologies Inc fragmentos de p97 e seus usos
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
KR101683635B1 (ko) * 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
CN104758250B (zh) * 2015-03-04 2021-06-01 王海龙 一种紫杉醇脂质体及其制备方法和用途
JP6804095B2 (ja) * 2015-06-10 2020-12-23 学校法人帝京大学 セラノスティクス用のバブル製剤（ｔｂ）及びその使用方法
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) * 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
US11357743B2 (en) 2017-04-19 2022-06-14 Mayo Foundation For Medical Education And Research Ketamine and propofol admixture
AU2019210204B2 (en) * 2018-01-18 2024-05-16 EndoProtech, Inc. Treating microvascular dysfunction
AU2019200325A1 (en) * 2018-01-31 2019-08-15 Liplasome Pharma Aps Methods for treating cancer and predicting drug responsiveness in cancer patients
CN110522728B (zh) * 2019-10-11 2022-03-15 上海市同仁医院 一种介孔二氧化硅纳米递药系统、制备方法及其应用
US20230285292A1 (en) * 2020-06-23 2023-09-14 The Trustees Of The University Of Pennsylvania Compositions and methods of using a pla2-responsive drug delivery system

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) * 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4963362A (en) 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
CA2013770A1 (en) * 1989-04-04 1990-10-04 Jack M. Shaw Use of liposomes for the delivery of therapeutic agents to wounds, cuts and abrasions
US5227170A (en) * 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US6027726A (en) 1994-09-30 2000-02-22 Inex Phamaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
CA2252055C (en) * 1996-04-11 2007-01-16 The University Of British Columbia Fusogenic liposomes
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
AU1656799A (en) 1997-12-12 1999-07-05 Inex Pharmaceuticals Corp. Cationic drugs encapsulated in anionic liposomes
US6911306B1 (en) 1999-10-18 2005-06-28 Emory University TMS1 compositions and methods of use
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
JP2003522193A (ja) * 2000-02-10 2003-07-22 リプラサム ファーマ アー／エス ホスホリパーゼａ２で分解可能な脂質誘導体を含有する脂質をベースとした薬物送達系、および治療におけるその使用
EP1839670A3 (en) * 2001-02-21 2009-11-11 Alavita Pharmaceuticals, Inc. Modified Annexin Proteins and their use against thrombosis
US20030026831A1 (en) * 2001-04-20 2003-02-06 Aparna Lakkaraju Anionic liposomes for delivery of bioactive agents
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
ES2387886T3 (es) 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Composiciones que transportan lípidos con una mejor estabilidad sanguínea
ATE373466T1 (de) * 2001-11-13 2007-10-15 Celator Pharmaceuticals Inc Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
US7273620B1 (en) 2002-05-20 2007-09-25 University Of British Columbia Triggered release of liposomal drugs following mixing of cationic and anionic liposomes
US20040018525A1 (en) 2002-05-21 2004-01-29 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
US7718160B2 (en) 2002-07-02 2010-05-18 The Board Of Regents Of The University Of Texas System Radiolabeled compounds and liposomes and their method of making and using same
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
US20040203069A1 (en) * 2003-04-10 2004-10-14 Chris Reutelingsperger Method for determining and/or isolating lipid-binding compounds
EP1622585A4 (en) * 2003-05-02 2009-07-01 Aronex Pharmaceuticals Inc LIPID-PLATINUM COMPLEXES AND APPLICATION METHOD THEREFOR
EP1643971A2 (en) * 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
US20050002999A1 (en) * 2003-06-04 2005-01-06 Rahul Mehta Long-circulating liposomal compositions
WO2005005601A2 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1547674A1 (en) 2003-12-23 2005-06-29 MediGene Oncology GmbH Method for producing colloidal nanoparticles
WO2005078139A2 (en) 2004-02-09 2005-08-25 Thomas Jefferson University DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
RU2424792C2 (ru) 2004-05-03 2011-07-27 Хермес Байесайенсиз, Инк. Липосомы, используемые для доставки лекарственных средств
WO2006025411A1 (ja) 2004-08-31 2006-03-09 Astellas Pharm. Inc. 細胞内薬物送達改善リポソーム
ATE418966T1 (de) 2004-11-03 2009-01-15 Liplasome Pharma As Arzneimittelabgabesysteme auf lipidbasis mit unnatürlichen phospholipase-a2-abbaubaren lipid- derivaten und ihre therapeutische verwendung
PE20070360A1 (es) * 2005-09-01 2007-04-19 Novartis Ag Composiciones de liposomas
US20100189771A1 (en) 2005-10-25 2010-07-29 Lawrence Mayer Fixed ratio drug combination treatments for solid tumors
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
JP5395439B2 (ja) 2006-01-05 2014-01-22 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 固形癌の診断及び治療のためのマイクロｒｎａに基づく方法及び組成物
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
WO2007123691A2 (en) * 2006-03-30 2007-11-01 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
WO2008006658A1 (en) * 2006-07-14 2008-01-17 Fmc Biopolymer As Hydrogels containing low molecular weight alginates and biostructures made therefrom
US20080069778A1 (en) * 2006-09-20 2008-03-20 Imarx Therapeutics, Inc. Polymer-encapsulated microspheres
US20090162425A1 (en) 2007-09-19 2009-06-25 University Of Tennessee Research Foundation Methods and compositions for inhibiting undesirable cellular proliferation by targeted liposome delivery of active agents
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
WO2011098578A2 (en) 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients

Also Published As

Publication number Publication date
JP5767580B2 (ja) 2015-08-19
EP2299977A2 (en) 2011-03-30
SI2299977T1 (sl) 2012-11-30
AU2009248673A1 (en) 2009-11-26
US20200171080A1 (en) 2020-06-04
PL2299977T3 (pl) 2013-01-31
CA2725529A1 (en) 2009-11-26
EP2123258A1 (en) 2009-11-25
CA2725529C (en) 2016-07-05
CN102065840B (zh) 2014-12-10
US11173178B2 (en) 2021-11-16
WO2009141450A3 (en) 2010-07-08
JP2011521913A (ja) 2011-07-28
EP2299977B1 (en) 2012-08-15
AU2009248673B2 (en) 2014-08-21
HRP20120776T1 (hr) 2012-10-31
PT2299977E (pt) 2012-09-07
ES2393170T3 (es) 2012-12-19
US20120009243A1 (en) 2012-01-12
WO2009141450A2 (en) 2009-11-26
DK2299977T3 (da) 2012-11-05
CN102065840A (zh) 2011-05-18

Similar Documents

Publication Publication Date Title
CY1115325T1 (el) Λιποσωματα για διανομη φαρμακων και μεθοδοι παρασκευης αυτων
CY1123187T1 (el) Θεραπευτικες μεθοδοι που αφορουν βλαστοκυτταρα καρκινου
CY1126136T1 (el) Μεθοδοι θεραπειας της αρθριτιδας
CY1124897T1 (el) Τροποποιημενα εξωκυτταρικα κυστιδια και χρησεις αυτων
CY1116075T1 (el) Νεες συνθεσεις λιποσωματων
CY1119167T1 (el) Αναστολεις toy nkcc για τη θεραπεια του αυτισμου
CY1120929T1 (el) Λιπιδια για συστασεις διανομης θεραπευτικου παραγοντα
CY1120641T1 (el) Βελτιωμενο σκευασμα λιπιδιων
AR119552A2 (es) Producción de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
WO2008109031A3 (en) Liposome carriers for in vivo delivery of fullerenes
MA32876B1 (fr) Anticorps dirigés contre l'angiopoïétine 2 humaine
WO2009129387A3 (en) Cationic lipids and uses thereof
CY1116435T1 (el) Ενωσεις βορονικου εστερα και φαρμακευτικες συνθεσεις αυτων
CY1113024T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου για τη θεραπεια της εξαρτησης ουσιων
NO20083927L (no) Kreftbehandlinger
MA34653B1 (fr) Sels du dimethylamide de l'acide 7-cyclopentyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylique et leurs procedes de fabrication
CY1111903T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου με αναλγητικη δραση
MX2015012201A (es) Formulaciones modificadas de liposomas de docetaxel.
EA200901270A1 (ru) Стимуляция иммунной реакции катионными липидами
EA201491726A1 (ru) Конъюгаты бороновых кислот олигонуклеотидных аналогов
WO2014057432A3 (en) Multicomponent lipid nanoparticles and processes for the preparation thereof
WO2009114475A3 (en) Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
CY1115595T1 (el) Αλατα ρασιγιλινης και φαρμακευτικη παρασκευη αυτων
GB201100516D0 (en) Method using fluorinated amphiphiles
TW200738253A (en) Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine